Introduction {#s1}
============

*Clostridium difficile* infection (CDI) is considered a major health problem with a point prevalence of 13.1/1000 in-patient [@pone.0056498-Jarvis1] and is increasing in incidence and mortality [@pone.0056498-Archibald1]--[@pone.0056498-Redelings1]. The CDI cost in the United States of America (USA) alone was conservatively estimated to exceed \$1.1 billion annually [@pone.0056498-Kyne1]. Risk factors associated with CDI acquisition are numerous and traditionally have included exposure to antibiotics, advanced age, comorbidities, enteral feeding, prolonged hospitalization, endoscopy and antineoplastic medications [@pone.0056498-Schuller1]--[@pone.0056498-Brown1].

The role of gastric acid suppression therapy has gained interest recently as a risk factor for CDI. Four recently published meta-analyses have suggested an association between gastric acid suppression therapy with proton pump inhibitors (PPI) and CDI [@pone.0056498-Kwok1]--[@pone.0056498-Tleyjeh1]. The United States Food and Drug Administration (FDA) recently warned the public about a possible association between CDI and PPI use [@pone.0056498-US1]. However, to date; there is no systematic review dedicated to evaluate the potential association between histamine ~2~ receptors antagonists (H~2~RAs) use and risk of CDI.

H~2~RAs are popular over-the-counter (OTC) drugs worldwide [@pone.0056498-Shi1]. Off -label use of H~2~RAs and substitution for physician care were reported in 46 % and 34% of the adult consumer, respectively [@pone.0056498-US1]. Masking serious conditions, missed diagnosis, and the potential for inappropriate use by patients are concerns about OTC use of H~2~RAs [@pone.0056498-Erwin1]. Nonetheless, the implications of OTC H~2~RAs use are not yet well defined.

Given the high prevalence of prescription use and OTC use of H~2~RAs and the increasing incidence and severity of CDI, we sought to systematically review the published literature that examined the association between H~2~RAs use and development of CDI following the MOOSE [@pone.0056498-Stroup1] and PRISMA [@pone.0056498-Liberati1] guidelines. We use the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) framework [@pone.0056498-Guyatt1] to interpret our findings.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

The search strategy and subsequent literature searches were performed by a medical reference librarian (PJE) with 37 years of experience. The initial strategy was developed in Ovid MEDLINE (1990 through January 2012), using MeSH (Medical Subject Headings) controlled vocabulary, and then modified for Ovid EMBASE (1990 through January 2012). Primary terms were: enterocolitis, pseudomembranous/ AND the therapeutic agents of interest: explode omeprazole, explode proton pump inhibitors, anti-ulcer agents, and explode histamine H~2~ antagonists (Explode allows including all of the specific drugs, without having to use all of the various terms, synonyms, brands and generic names.) Articles were limited to randomized controlled trials, cohort studies, and or case-control studies. The same process was used with Ovid EMBASE with alterations as necessary to accommodate EMBASE\'s more granular subject headings. ISI Web of Science and Elsevier Scopus use text words: (difficile OR pseudomembranous OR pseudo-membranous) AND (omeprazole OR "proton pump" OR ranitidine OR h2 OR h-2 OR "acid suppression" OR antacid\*)) AND (random\* OR trial\* OR blind\* OR cohort\* OR controlled OR prospective). Moreover, bibliographic references of all articles and previous meta-analyses were searched for eligible studies. We have designed the search strategy to capture any association between gastric acid suppression therapy and development of CDI.

There was no restriction to language. All results were downloaded into EndNote 7.0 (Thompson ISI Research soft, Philadelphia, Pennsylvania), a bibliographic database manager, and duplicate citations were identified and removed. Two authors (A.B.A. and F.A.) independently assessed the eligibility of identified studies.

Study selection {#s2b}
---------------

To be included, a study had to: (1) be an analytical study; and (2) examine the association between H~2~RAs use and incidence of CDI in adult population.

Data collection {#s2c}
---------------

A data collection form was developed and used to retrieve information on relevant features and results of pertinent studies. Two reviewers (A.B.A. and F.A.) independently extracted and recorded data in a predefined checklist. Disagreements among reviewers were discussed with two other reviewers (I.M.T. and M.A.A.), and agreement was reached by consensus. We collected adjusted effect estimates and 95% confidence intervals (CI) based on the multivariable regression model used in each study.

We used the Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies [@pone.0056498-Wells1] which is intended to rate selection bias, comparability of the exposed and unexposed groups of each cohort, outcome assessment, and attrition bias. Two reviewers (M.A.G and F.A.) independently assessed the methodological quality of selected. Disagreement among reviewers was discussed with 2 other reviewers (I.M.T. and M.A.A.), and agreement was reached by consensus.

We used the GRADE framework to interpret our findings. The Cochrane Collaboration has adopted the principles of the GRADE system [@pone.0056498-Guyatt1] for evaluating the quality of evidence for outcomes reported in systematic reviews.

For purposes of systematic reviews, the GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest. Quality of a body of evidence involves consideration of within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias.

Statistical Analyses {#s2d}
--------------------

### Meta-analyses {#s2d1}

The primary effect measures used in the meta-analysis were Odds Ratios (OR), Hazard Ratios (HR) and Relative Risks (RR) which were assumed to reasonably estimate the same association between CDI and H~2~RAs given the low incidence of CDI and thus were pooled together. Adjusted effect estimates were primarily used for this analysis. Unadjusted effect estimates were used as alternatives if studies did not pursue adjustment because of absence of association on univariate comparison.

Effect estimates from all included studies were pooled in a meta-analysis weighing individual studies according to their log-transformed inverse variance. The DerSimonian and Laird random effects model [@pone.0056498-DerSimonian1] was used to calculate the pooled effect estimates.

We extracted data on the proportion of CDI cases that were exposed to antibiotics from all studies that reported these data. We then performed a meta-analysis for the proportion on logit scale using random effects model weighing the individual studies according to their log-transformed inverse variance.

### Exploring heterogeneity {#s2d2}

Homogeneity among studies was tested by means of Cochran\'s Q test and calculation of the variation across studies attributable to heterogeneity rather than chance (I^2^). The influence of a range of a-priori selected study-level and aggregated individual-level parameters on the observed effect estimate was investigated by means of meta-regressions. In these analyses, the log odds ratio from each study was regressed on the potential confounders in univariate and multivariate weighted linear regressions, weighted according to the inverse standard error and the residual between-study variance. Ten potential confounders were considered. Seven variables were categorical: design of the study (case-control vs. cohort), country of publication, setting (single center vs. multicenter), method of ascertainment of antibiotic use, method of effect measure (OR vs. RR/HR), effect estimate (adjusted vs. unadjusted) and quality of included studies (high score vs. low score). Three continuous variables were: the impact factor of the journal where the study was published, number of variables the effect measure was adjusted for and proportion of cases that were exposed to antibiotics.

### Publication bias {#s2d3}

The possible influence of publication bias was graphically assessed with the novel method of contour-enhanced funnel plot where log-transformed odds ratios were plotted against standard errors. This method examines whether any funnel plot asymmetry is likely to be due to publication bias compared with other underlying causes of funnel plot asymmetry. The contours help to indicate whether areas of the plot, where studies are perceived to be missing, are where studies would have statistically significant effect sizes or not and thus decrease or increase the evidence that the asymmetry is due to publication bias. The presence of funnel plot asymmetry was also assessed using Egger\'s test [@pone.0056498-Egger1].

### Residual confounding {#s2d4}

Finally, the possible influence of unknown confounders (residual confounding) was investigated with a rule-out approach described by Schneeweiss [@pone.0056498-Schneeweiss1]. This approach stipulates the influence of a hypothetical confounder and determines what characteristics this confounder must have to fully account for the observed association between use of H~2~RAs and occurrence of CDI. The hypothetical confounder is characterized by its association to H~2~RAs use (OR~EC~, odds ratio of exposure to the confounder) and its association to the outcome (RR~CO~, relative risk of outcome in individuals exposed to the confounder vs. non-exposed). For this analysis, the absolute risk in the pooled non-exposed group was used for conversion of odds ratio to relative risk using the method described by Zhang and Yu [@pone.0056498-Zhang1]. Separate analyses were performed to demonstrate what levels of OR~EC~ and RR~CO~ would be required to fully explain the observed association between H~2~RAs and CDI for different hypothetical prevalence of the unknown confounder (i.e. P~C~ = 0.2, P~C~ = 0.4) before and after adjustment for publication bias as described above.

In all analyses, results associated with p-values \<0.05 (two-sided test) were considered statistically significant. All statistical analyses were performed using Stata version 12 statistical software (StataCorp, College Station, Texas).

Results {#s3}
=======

Search results {#s3a}
--------------

The search yielded 27 eligible studies after excluding 260 citations. Six more studies were retrieved from recent review articles and added to the total eligible studies. Kutty [@pone.0056498-Kutty1] et al and Jayatilaka [@pone.0056498-Jayatilaka1] et al, each reported 2 different observations for different participants. Thus, a total of 33 articles met our inclusion criteria representing 35 observations that included 201834 participants. There was excellent agreement for the inclusion of the studies, data abstraction and quality assessment between the reviewers (kappa statistic being 1.0, 1.0 and 0.91 respectively).

The study selection process is illustrated in [Figure 1](#pone-0056498-g001){ref-type="fig"} and the main characteristics of the included studies are summarized in [Table 1](#pone-0056498-t001){ref-type="table"}. Twenty-four case control studies [@pone.0056498-Kutty1]--[@pone.0056498-Sundram1], [@pone.0056498-Novell1], [@pone.0056498-Manges1]--[@pone.0056498-Naggie1], [@pone.0056498-Dial4]--[@pone.0056498-Yip1] and 11 cohort studies [@pone.0056498-Howell1]--[@pone.0056498-Dial3], [@pone.0056498-Netland1]--[@pone.0056498-Loo2], [@pone.0056498-Stevens1] reported data on both community-acquired and hospital-acquired CDI (8 observations were from community-acquired CDI, 23 from hospital-acquired CDI and 4 representing both type of CDI). Six studies [@pone.0056498-Kutty1], [@pone.0056498-Dalton1], [@pone.0056498-Jung1], [@pone.0056498-Naggie1], [@pone.0056498-Dial4], [@pone.0056498-McFarland1] were from multiple centers; two from UK general practice research database [@pone.0056498-Nath1], [@pone.0056498-Dial1], and the remaining were from single centers. The included studies were performed in 6 countries (17 studies from USA, 9 from Canada, 6 from United Kingdom, 1 from Netherlands, 1 from Israel, and one from Korea). Most studies did not specify the type or duration of therapy with H~2~RAs. [Tables 2](#pone-0056498-t002){ref-type="table"} and [3](#pone-0056498-t003){ref-type="table"} summarized the case ascertainment, control or non-exposed group selection method for case control and cohort studies, respectively. Among all citations, seventeen studies reported the proportion of cases exposed to antibiotics. Eight studies used antibiotics exposure as inclusion criteria. Three studies did not provide either the absolute number of exposed or unexposed groups thus were not included in this pooled proportion analysis.

![Flow diagram of eligible studies.](pone.0056498.g001){#pone-0056498-g001}

10.1371/journal.pone.0056498.t001

###### Characteristics of the included studies.
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  Source                             Country     Centers       Setting              Condition             Study Design                                          Inclusion Criteria                                                       Acid Suppression Therapy
  --------------------------------- --------- ------------- -------------- --------------------------- ------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------
  **Kutty et al (VA),^26^2010**        US      Multicenter    Community              Gen Pop              Case-control                                   Age: ≥18 yr; Communityonset CDAD                                        **H~2~RAs: exposure 3mo prior to test**
  **Kutty et al (D),^26^ 2010**        US      Multicenter    Community              Gen Pop              Case-control                                   Age: ≥18 yr; Communityonset CDAD                                        **H~2~RAs: exposure 3mo prior to test**
  **Nath et al, ^28^1994**             CA        Single        Hospital           Hem-onco pts            Case-control                                        Adult; In-patient \>3d                                                   **Acid suppression therapy**
  **Jayatilaka et al, ^27^ 2007**      US        Single        Hospital          Gen In-patient           Case-control                                               Age \>18                                                           **H~2~RAs: pre admission**
  **Jayatilaka et al,^27^2007**        US        Single        Hospital          Gen In-patient           Case-control                                               Age \>18                                                          **H~2~RAs: post admission**
  **Shah et al (D),^29^ 2000**         UK        Single        Hospital          Gen In-patient           Case-control                              Age \>65 yr; Gen medical/elderlycare wards                                   **H~2~RAs: upto 16 wk before diarrhea**
  **Dial et al, ^30^ 2005**            UK         GPRD        Community              Gen Pop              Case-control               Age ≥18 yr; At least 2 yrs of recordsin the GPR; firstoccurrence of CDAD                   **H~2~RAs: 90 d prior to the index date**
  **Debast et al, ^31^ 2009**          NL        Single        Hospital          Gen In-patient           Case control                                           Age:≥18 yr; CDAD                                                         **H~2~RAs: exposure**
  **Lowe et al, ^32^ 2006**            CA        Single       Community              Gen Pop            Case-control (R)       1 hospital admission for CDAD; Age ≥ 66yr; CDAD diagnosis within 60d of ABX therapy                        **H~2~RAs: exposure**
  **Dial et al, ^33^ 2006**            UK         GPRD        Community            General pop            Case-control           First prescription oral Vancomycin; No previous admission 1yr before index date                   **H~2~RAs: 90d prior to index date**
  **Aseeri et al, ^34^ 2008**          US        Single        Hospital          Gen In-patient           Case-control                                      Age ≥18 Yr; Inpt for ≥3 d                                                  **H~2~RAs: 3d before CDAD**
  **Dubberke et al,^35^ 2007**         US        Single        Hospital          Gen In-patient           Case- Control                            Pts admitted for \>48 hrbetween study period                                                **H~2~RAs**
  **Loo et al, ^36^ 2005**             UK        Single        Hospital          Gen In-patient           Case-control                                       Hospital Acquired CDAD;                                                **H~2~RAs: 6wk before diagnosis**
  **Sundram et al,^37^ 2009**          UK        Single        Hospital          Gen In-patient           Case-control                                     Adult HospitalAcquired CDAD                                               **H~2~RAs: 6wk prior to onset**
  **Howell et al,^38^ 2010**           US        Single        Hospital          Gen In-patient              Cohort                                 Age ≥18 yr; LOS ≥3 d;Only first diagnosis                                                  **H~2~RAs**
  **Dalton et al, ^39^ 2009**          CA      Multicenter     Hospital     Med/Surgical Subspecialty      Cohort, (R)                              Age: ≥18 yr; Minimum 7-dLOS; ABX exposure                                                  **H~2~RAs**
  **Dubberk et al,^40^2007**           US        Single        Hospital          Gen In-patient            Cohort, (R)                            All pts admitted to BJHfor more than 48 hours                                                **H~2~RAs**
  **Pepin et al,^41^ 2005**            CA        Single        Hospital          Gen In-patient            Cohort, (R)                                           Adult In-patient                                                              **H~2~RAs**
  **Beaulieu et al, ^42^ 2007**        CA        Single        Hospital            Medical ICU               Cohort            ICU LOS\>24hr; Diarrhea \>24 hr and positive CD toxin (2d to 2monthspost discharge)                             **H~2~RAs**
  **Peled et al, ^43^ 2007**           IL        Single        Hospital          Gen In-patient            Cohort, (P)                    CD testing during 4m period; ABX within 40d prior to diarrhea                                        **H~2~RAs**
  **Dial et al, ^44^ 2004**            CA        Single        Hospital       Med/CT/Surgical wards          Cohort         Pharmacy database; ABX during studyperiod; positive toxin in theinfection control registry                         **H~2~RAs**
  **Novell et al, ^45^, 2010**         US        Single        Hospital          Gen Inpatients         Case-control, (R)                                        Age ≥18 yr; CDAD                                                              **H~2~RAs**
  **Netland et al, ^46^ 2011**         US        Single          Both                Gen Pop               Cohort, (R)                                            Recurrent CDI                                                                **H~2~RAs**
  **Jung et al, ^47^ 2010**           Korea      Single        Hospital          Gen Inpatients         Cohort study, (R)                            Recurrent CDAD ortreatment failure cases                                                  **H~2~RAs**
  **Loo et al, ^48^ 2011**             CA      Multicenter     Hospital          Gen Inpatients          Cohort study(P)                               Age ≥18, Health CareAssociated CDAD                                                     **H~2~RAs**
  **Manges et al, ^49^ 2010**          CA        Single        Hospital          Gen Inpatients           Case control                                           Nosocomial CDAD                                                               **H~2~RAs**
  **Kuntz et a,l^50^ 2011**            US        Single       Community              Gen Pop            Case control, (R)                                    CommunityAssociated CDAD                                                  **Acid suppression therapy**
  **Naggie et al,^51^ 2011**           US      Multicenter    Community              Gen Pop              Case control                                              Age≥18 yr                                                          **Acid suppression therapy**
  **Stevens et al,^52^, 2011**         US        Single        Hospital          Gen Inpatients            Cohort, (R)                                     Age ≥18 yr,Hospital acquired                                                        **H~2~RAs**
  **Dial et al, ^53^ 2008**            CA      Multicenter    Community         Elderly patients          Case control                                  Age ≥65, CommunityAssociated CDAD                                                      **H~2~RAs**
  **McFarland et al,^54^ 2007**        US      Multicenter       Both                Gen Pop              Case control                                            CDAD Diagnosis                                                               **H~2~RAs**
  **Kazakova et al,^55^ 2012**         US        Single          Both                Gen Pop              Case control           CDAD Diagnosis, onset duringthe pre-outbreak or outbreakperiods, hospitalization                              **H~2~RAs**
  **Modena et al,^56^ 2005**           US        Single          Both                Gen Pop              Case control                  Received at least 5 daysof antibiotics prior to diagnosis of CDAD                                      **H~2~RAs**
  **Muto et al,^57^ 2005**             US        Single        Hospital          Gen Inpatients           Case control                                           Nosocomial CDAD                                         **H~2~RAs: During the 4 weeks before detection of CDAD**
  **Yip et al, ^58^ 2001**           **CA**    **Single**    **Hospital**      **Gen Inpatients**       **Case control**                                       **Nosocomial CDAD**                                                             **H~2~RAs**

Abbreviations: US, United States;UK, United Kingdom; BMT, Bone Marrow Transplant; ESRD, End Stage Renal Disease; GPRD -- general practice research database; IBD, Inflammatory Bowel Disease; CD, Clostridium Difficile; CDAD, Clostridium difficile associated diarrhea; LOS, Length of Stay; LTCF, Long Term Care Facility; Gen, General.; Pop, Population; d, day/days; mo, month/months; yr, year/year; wk, week/week; Pts, Patients; Pt, Patient; Med, Medical; CT, Cardio-thoracic; NL, Netherland; CA, Canada; IL, Israel; Abd, Abdominal; (P), prospective; (R), Retrospective.\*, Mostly hospital.

10.1371/journal.pone.0056498.t002

###### The Association between H~2~RAs use and development of *Clostridium difficile* infection from case-control studies.
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  Source                                               Case Ascertainment                                                                      Selection of Controls                                                                                    Sample size                                                                      Adjusted Effect Estimates
  ---------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  Kutty et al,^26^ (VA)                        Non-formed stool,Positive CD toxin                                        Randomly selectedfrom the same geographicaloutpatients territory                                                  Exposed group; cases:7, controls: 13                                                          Crude OR, 1.8 (0.6--4.8)
                                                                                                                                                                                                                                         Non-exposed group;cases: 29, controls: 95                        
  Kutty et al,^26^ (D)                         Non-formed stool,Positive CD toxin                                        Randomly selected fromthe same geographical outpatients territory                                                  Exposed group; cases:6, controls: 3                                                          Crude OR, 1.3 (0.3--5.6)
                                                                                                                                                                                                                                         Non-exposed group;cases: 67, controls: 45                        
  Sundram et al,^37^ 2009               Diarrhea, Positive stoolfor CD toxin, ribotyped                                        Inpatients, No diarrhea, Nevertested positive for CD                                                        Exposed group; cases:65, controls: 52                                                  Crude OR for PPI/ H~2~RAs :1.7, P 0.456
                                                                                                                                                                                                                                         Non-exposed group;cases: 32, controls: 45                        
  Jayatilaka et al,^27^ 2007                        Diarrhea, Positive toxin                                                          Age and sex matched,Same period of time                                                               H~2~RAs use pre andduring admission                                                     H~2~RAs use pre andduring admission
                                                                                                                                                                                                                                           Exposed group; cases:9, controls: 17                                                             OR: 0.95(0.39-2.34)
                                                                                                                                                                                                                                         Non-exposed group;cases: 6, controls: 14                         
  Jayatilaka et al,^27^ 2007                        Diarrhea, Positivetoxin                                                           Age and sex matched,Same period of time                                                                    H~2~RAsuse post admission                                                               H~2~RAsuse post admission
                                                                                                                                                                                                                                          Exposed group; cases:133, controls: 227                                                           OR: 0.73(0.26-2.06)
                                                                                                                                                                                                                                        Non-exposed group;cases: 116, controls: 230                       
  Loo et al,^36^ 2005           Diarrhea/positive CD, Endoscopicdiagnosis, histological evidence                            Matched to Age,Charlson index, date ofadmission, ward, LOS                                                     Exposed group; cases:47, controls: 47                                     Diarrhea/positive CD, Endoscopicdiagnosis, histological evidence
                                                                                                                                                                                                                                        Non-exposed group;cases: 190, controls: 190                       
  Shah et al,^29^ 2000                        Diarrhea Positivestool for CD toxin                                           Negative stool toxins,Similar age, Hospitalward, Same time                                                     Exposed group; cases:22, controls: 22                                                                 Diarrhea
                                                                                                                                                                                                                                        Non-exposed group;cases: 104, controls: 104                                                     Positive stoolfor CD toxin
  Dial et al,^33^ 2006                 Patients with first prescriptionof oral Vancomycin                                                      Age matched,Same ward                                                                      Exposed group; cases:23, controls: 112                                            Patients with first prescriptionof oral Vancomycin
                                                                                                                                                                                                                                       Non-exposed group;cases: 294, controls: 2055                       
  Asseri et al,^34^ 2008                                    Diarrhea                                        Matched to date ofadmission, antibiotic use, gender, age group, patient location, room type                                    Exposed group; cases:17, controls: 9                                                                  Diarrhea
                                                   Positive stoolfor CD toxin                                                                                                                                                            Non-exposed group;cases: 77, controls: 85                                                      Positive stoolfor CD toxin
  Dial et al,^30^ 2005                                 Positive CD toxin                           Same general practice,Not hospitalized in the yearprior to index date, Negative CD toxin, No diagnosis of CDI                          Exposed group;cases: 83, controls: 367                                                             Positive CD toxin
                                                  Clinical diagnosismade by GP                                                                                                                                                          Non-exposed gp;cases: 1150, controls: 11963                                                    Clinical diagnosismade by GP
  Lowe et al,^32^ 2006                                        CDAD                                                                    Matched to age, sex,and antibiotic use                                       Exposed group; cases: 213, controls: 1846Non-exposed gp; cases: 1176, controls: 10457   Exposed group; cases: 213, controls: 1846Non-exposed gp; cases: 1176, controls: 10457
  Debast et al,^31^ 2009                                    Diarrhea                                                       Randomly selected frothe same time and same wards asCDI cases                                                    Exposed group; cases:2, controls: 2                                                     Exposed group; cases:2, controls: 2
                                                   Positive stoolfor CD toxin                                                                                                                                                            Non-exposed group;cases: 43, controls: 88                                               Non-exposed group;cases: 43, controls: 88
  Nath et al,^28^ 1994                                      Diarrhea                                                                      Age matched,Same hospital unit                                                                   Exposed group; cases:51, controls: 32                                                   Exposed group; cases:51, controls: 32
                                                   Positive stoolfor CD toxin                                                                                                                                                            Non-exposed group;cases:29, controls: 48                                                Non-exposed group;cases:29, controls: 48
  Dubberke et al,^35^ 2007                                  Diarrhea                                                                 Randomly selectedDuring the study period                                                             Exposed group; cases:206, controls: 426                                                 Exposed group; cases:206, controls: 426
                                                   Positive stoolfor CD toxin                                                                                                                                                          Non-exposed group;cases: 176, controls: 1102                                            Non-exposed group;cases: 176, controls: 1102
  Novell et al,^45^ 2010                                  New diarrhea                                                       Matched to in-patient unit,age, gender, date of admission                                                     Exposed group; cases:12, controls: 07                                                   Exposed group; cases:12, controls: 07
                                                   Positive stoolfor CD toxin                                                                                                                                                           Non-exposed group;cases: 162, controls: 167                                             Non-exposed group;cases: 162, controls: 167
  Manges et al,^49^ 2010        Diarrhea/positive CD, Endoscopicdiagnosis, histological evidence                                  Matched to Age, gender,date of hospitalization                                                           Exposed group; cases:09, controls: 12                                                   Exposed group; cases:09, controls: 12
                                                                                                                                                                                                                                         Non-exposed group;cases: 16, controls: 38                                               Non-exposed group;cases: 16, controls: 38
  Kuntz et al,^50^ 2011                                 ICD-9 code, CDAD                                                                         Randomly selected                                                                        Exposed group; cases:55, controls: 157                                                  Exposed group; cases:55, controls: 157
                                                                                                                                                                                                                                       Non-exposed group;cases: 249, controls: 2883                                            Non-exposed group;cases: 249, controls: 2883
  Naggie et al,^51^ 2011                                    Diarrhea                                                                       Matched by geographiclocation                                                                   Exposed group; cases:22, controls: 44                                                   Exposed group; cases:22, controls: 44
                                                   Positive stoolfor CD toxin                                                                                                                                                            Non-exposed group;cases: 44, controls: 70                                               Non-exposed group;cases: 44, controls: 70
  Dial et al,^53^ 2008                               ICD-9 code008.45, CDAD                                        Randomly selected, matchedto index date and date of first hospital admission                                                             NR                                                                              RR:1.60 (0.90-2.20)
  McFarland et al,^54^ 2007          Acute diarrhea Culture positive or positive C.D toxins                                              Matched to time ofCDAD, Age, Ward                                                                Exposed group; cases:24, controls: 160                                                                    NR
                                                 No other causefor the diarrhea                                                                                                                                                         Non-exposed group;cases: 23, controls: 161                        
  Kazakova et al,^55^ 2012                        Diarrhea, positiveCD toxin A                                                          Matched to Sex, Age,admission date                                                                 Exposed group;cases:19, controls: 49                                                             OR:2.69(1.22-5.97)
                                                                                                                                                                                                                                        Non-exposed group;cases: 18, controls: 109                        
  Modena et al,^56^ 2005                                    Diarrhea                                                            Inpatients, Receivedantibiotics for at least 5 days                                                         Exposed group;cases:32, controls:18                                                                     NR
                                                  Positive stoolfor CD toxins                                                                                                                                                           Non-exposed group;cases: 98, controls: 102                        
  Muto et al,^57^ 2005                                      Diarrhea                                                Matched to admission date,Type of medical service, Length of hospital stay                                             Exposed group;cases:159, controls:44                                                             OR:2.00(1.10-3.50)
                                                   Positive stoolfor CD toxin                                                                                                                                                           Non-exposed group; cases: 141, controls: 62                       
  Yip et al,^58^ 2001                                       Diarrhea                                                                   Matched to Age,Gender, admission date                                                                Exposed group;cases:14, controls:13                                                            OR:2.70(0.71--10.10)
                                                   Positive stoolfor CD toxin                                                                                                                                                            Non-exposed group;cases: 9, controls: 18                         

10.1371/journal.pone.0056498.t003

###### The Association between H2RAs use and development of *Clostridium difficile* infection from cohort studies.
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  Source                                                      Case Ascertainment                                                                     Selection of Controls                                                                             Sample size                                            Adjusted Effect Estimates
  ------------------------------ ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------
  **Howell et al,^38^ 2010**                                   Positive CD toxin                                                       A nearest-neighbor--matching algorithmwas applied                                                Exposed group; cases: 66,controls: 10619                                OR : 1.53 (1.12--2.10)
                                                                                                                                                                                                                                      Non-exposed group; cases:599,controls: 90512                       
  **Dalton et al,^39^ 2009**        Positive stool toxins or colonoscopy-confirmed psudomembraneous colitis                           Age, ≥ 18 years, Minimum7d LOS, Antibiotic exposure                                                Exposed group; cases:28 controls: 2135                                  OR, 1.70 (1.09 2.64)
                                                                                                                                                                                                                                      Non-exposed group;cases:121, controls: 12435                       
  **Dubberk et al,^40^ 2007**                                Positive stool for CD                              In-patient, No positivestool toxin assay during the period(60d before startof study to the end)   Exposed group; cases: 206,controls: 998 Non-exposed group;cases: 176, controls: 25716           OR, 2.0 (1.6-2.6)
  **Pepin et al, ^41^ 2005**               Diarrhea, Positive toxin, provenpseudomembranous colitis                                                         Unclear                                                                      Exposed group; cases:1199, controls: NR                                 HR, 1.07 (0.8-1.43)
                                                                                                                                                                                                                                        Non-exposed gp; cases:6222, controls: NR                         
  **Beaulieu et al,^42^ 2007**                        DiarrheaPositive stool for CD toxin                                                                   Unclear                                                                      Exposed group; cases:470, controls: NR                                 HR, 0.78 (0.5 -- 1.23)
                                                                                                                                                                                                                                       Non-exposed group;cases: 357, controls: NR                        
  **Peled et al,^43^ 2007**                           DiarrheaPositive stool for CD toxin                                             Diarrhea with negativestool for CD, sameinstitution                                                 Exposed group; cases:22, controls: 45                                OR, 3.1 P value : 0.024
                                                                                                                                                                                                                                       Non-exposed group;cases: 30, controls: 120                        
  **Dial et al,^44^ 2004**                                Positive stoolfor CD toxins                                                                       Unclear                                                                       Exposed group; cases:NR, controls: NR                                   OR : 1.1 (0.4-3.4)
                                                                                                                                                                                                                                        Non-exposed group;cases: NR, controls: NR                        
  **Netland et al, ^46^ 2011**           Diarrhea between 5--60 daysafter antibiotic therapy for CDAD                                      Patients with CDAD inthe same institution                                                      Exposed group; cases:05, controls: 50                                OR, 0.49 P value : 0.33
                                                                                                                                                                                                                                        Non-exposed group;cases: 50, controls: 99                        
  **Jung et al,^47^ 2010**                    Diarrhea or pseudomembranouscolitis, Positive toxin                                                      Same institution                                                                   Exposed group; cases:06, controls: 31                                OR, 1.59 P value : 0.367
                                                                                                                                                                                                                                        Non-exposed group;cases: 08, controls: 66                        
  **Loo et al,^48^ 2011**         Diarrhea and: positive CD, histological evidenceor pseudomembranous colitis                                     Frequency matchingapproach                                                              Exposed group; cases:NR, controls: NR                                OR : 0.55 (0.21 -- 1.49)
                                                                                                                                                                                                                                       Non-exposed group;cases: 190, controls: 190                       
  **Stevens et al,^52^ 2011**                         Diarrhea Positivestool for CD toxin                                                              Same institution                                                                  Exposed group; cases:23, controls: 1060                          HR, 1.7 (0.7 -- 3.9), P value 0.25
                                                                                                                                                                                                                                      Non-exposed group;cases: 218, controls: 8853                       

Quality assessment {#s3b}
------------------

Quality assessment of all included studies was done using the validated Newcastle-Ottawa Quality Assessment Scale [@pone.0056498-Wells1] for cohort and case control studies ([Tables 4](#pone-0056498-t004){ref-type="table"} and [5](#pone-0056498-t005){ref-type="table"}). Included studies were scored based on the sum number of the stars given to each study. Among case-control studies, Loo et al 2011, Manges et al 2010, McFarland et al 2007, Modena et al 2005 and Dial et al 2008 scored the lowest. While Beaulieu et al 2005 scored the lowest among cohort studies. Most studies were of good quality with no evidence of selection bias, and with good comparability of the exposed and unexposed groups of each cohort, and outcome assessment.

10.1371/journal.pone.0056498.t004

###### Modified Newcastle-Ottawa quality assessment scale for case-control studies included in the meta-analysis.

![](pone.0056498.t004){#pone-0056498-t004-4}

                                Selection[\*](#nt102){ref-type="table-fn"}                                        Exposure[0](#nt108){ref-type="table-fn"}                                                                                                                                                          
  ---------------------------- -------------------------------------------- ------------------------------------ ------------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ --- ---
  Kutty et al,^26^ 2010.            A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   7
  Nath et al,^28^1994               A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   7
  Jayatilaka et al,^27^ 2007                        B                        A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Shah et al,^29^ 2000              A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Lowe et al,^32^ 2006              A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   7
  Dial et al,^30^ 2005              A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   C   8
  Dial et al,^33^ 2006                              B                                        A                       A[\*](#nt102){ref-type="table-fn"}                      A                    A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   C   5
  Aseeri et al,^34^ 2008            A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                                  E                    B[\*](#nt102){ref-type="table-fn"}   C   6
  Dubberke et al,^35^ 2007          A[\*](#nt102){ref-type="table-fn"}                       B                                       B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Loo et al,^36^ 2005               A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}                   E                    A[\*](#nt102){ref-type="table-fn"}   C   5
  Sundram et al,^37^ 2009           A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Novell et al,^45^ 2010            A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   7
  Debast et al,^31^ 2009            A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Kuntz et al,^50^ 2011             A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   7
  Manges et al,^49^ 2010            A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                                       B                    A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   5
  Naggie et al,^51^ 2011            A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}      A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}                   C                    A[\*](#nt102){ref-type="table-fn"}   C   6
  McFarland et al,^54^ 2007                         B                        A[\*](#nt102){ref-type="table-fn"}                      C                       A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Modena et al,^56^ 2005                            B                        A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   5
  Muto et al,^57^ 2005                              B                        A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Yip, et al,^58^ 2001                              B                        A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                  A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   6
  Dial et al,^53^ 2008                              B                        A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   A[\*](#nt102){ref-type="table-fn"}   C   5
  Kazakova et al,^55^ 2006          A[\*](#nt102){ref-type="table-fn"}       A[\*](#nt102){ref-type="table-fn"}                      B                       A[\*](#nt102){ref-type="table-fn"}                 A\*\*                                  D                    A[\*](#nt102){ref-type="table-fn"}   C   6

Selection:

(1)Is this case definition adequate? A, yes, with independent validation; B, yes, eg record linkage or based on self reports C, no description.

\(2\) Representativeness of the cases: A, Consecutive or obviously representative series of cases; B, Potential for selection biases or not stated.

\(3\) Selection of controls: A, Community controls; B, Hospital controls; C, No description.

\(4\) Definition of controls: A, No history of disease; B, No description of source.

Comparability: Comparability of cases and controls on the basis of the design or analysis: A, study controls for co-morbidities; B, study controls for any additional factor (e.g., age and severity of illness).

Exposure:

Ascertainment of exposure: A, Secured records; B, Structured interview where blind to case/control status; C, Interview not blinded to case/control status; D, written self report or medical record only.

Same method of ascertainment for cases and controls; A, yes; B, no.

Non-response rate: A, Same for both groups; B, Non-respondents described; C, Rate different and no designation.

10.1371/journal.pone.0056498.t005

###### Modified Newcastle-Ottawa Quality Assessment Scale for Cohort studies included in the Meta-analysis
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                          Selection[\*](#nt112){ref-type="table-fn"}                                        Outcome[0](#nt118){ref-type="table-fn"}                                                                                                                                                                                           
  ---------------------- -------------------------------------------- ------------------------------------ ----------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------ ---
  Howell et al,2010           A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  B[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   9
  Dalton et al, 2009          A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  B[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   9
  Dubberke et al, 2007        A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  B[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   9
  Pepin et al, 2005           A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   B[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   8
  Beaulieu et al, 2007                        B                        A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   7
  Peled et al, 2007           A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}                      B                      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   8
  Loo et al 2011              A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}                      B                      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   8
  Netland et al, 2011         A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  B[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   9
  Jung et al, 2010            A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  B[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   9
  Stevens et al, 2011         A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}                 A\*\*                  B[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   9
  Dial et al 2004             A[\*](#nt112){ref-type="table-fn"}       A[\*](#nt112){ref-type="table-fn"}     A[\*](#nt112){ref-type="table-fn"}      A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   A[\*](#nt112){ref-type="table-fn"}   8

Selection:

\(1\) Representativeness of the exposed cohort: A, truly representative; B, somewhat representative; C, selected group; D, no description of the derivation of the cohort.

\(2\) Selection of the non-exposed cohort: A, drawn from the same community as the exposed cohort; B, drawn from a different source; C, no description of the derivation of the non-exposed cohort.

\(3\) Ascertainment of exposure: A, secure record; B, structured interview; C, written self-report; D, no description.

\(4\) For demonstration that the outcome of interest was not present at start of study: A, yes; B, no.

Comparability: For comparability of cohorts on the basis of the design or analysis: A, study controls for co-morbidities; B, study controls for any additional factor (e.g., age and severity of illness); C, not done.

Outcome:

\(1\) Assessment of outcome: A, independent blind assessment; B, record linkage; C, self-report; D, no description.

\(2\) Was follow-up long enough for outcomes to occur? A, yes, (i.e. in-hospital or up to 30 d); B, no.

\(3\) Adequacy of follow-up of cohorts: A, complete follow-up and all subjects accounted for; B, subjects lost to follow-up was unlikely to introduce bias, because a small number were lost or a description was provided of those lost; C, follow-up rate 90% or lower (select an adequate percentage) and no description of those lost; D, no statement.

Meta-analysis {#s3c}
-------------

Thirty-five observations from 33 eligible studies were pooled using a random effect model meta-analysis. We excluded the study by Jenkins et al. as an outlier due to its large standard error. The pooled effect estimate was 1.44, 95% CI (1.22--1.7), I^2^ = 70.5%. The pooled effect estimate for high quality studies was 1.39 (1.15--1.68), I^2^ = 72.3%.

Although the heterogeneity between the analyzed studies was moderate, the majority of studies pointed towards a positive association. [Figure 2](#pone-0056498-g002){ref-type="fig"} shows the forest plot and the pooled effect estimate for all studies stratified by country. [Table 6](#pone-0056498-t006){ref-type="table"} summarizes the pooled estimates and associated heterogeneity across different subgroups. The pooled proportion of CDI cases that were exposed to antibiotics was 0.81, 95% CI (0.65--0.91) as shown in [Figure 3](#pone-0056498-g003){ref-type="fig"}.

![Forest plot-random effect model meta-analysis of the association between CDI and H2RAs based on 35 observations stratified by country.\
Error bars indicate confidence interval.](pone.0056498.g002){#pone-0056498-g002}

![Forest plot of the pooled proportion of *Clostridium difficile* cases that were exposed to antibiotics.](pone.0056498.g003){#pone-0056498-g003}

10.1371/journal.pone.0056498.t006

###### Influence of study type and country on the pooled effect estimate and its associated heterogeneity.

![](pone.0056498.t006){#pone-0056498-t006-6}

  Group                   Pooled Effect Estimate (95 % CI)   I^2^ %   Number of Observations
  ---------------------- ---------------------------------- -------- ------------------------
  All studies                    1.44 (1.22, 1.70)            70.5              35
  Case-control studies           1.58 (1.28, 1.95)            68.9              24
  Cohort studies                 1.19 (0.87, 1.62)            75.6              11
  Asia                           1.86 (1.07, 3.22)             0                2
  Canada                         1.25 (0.97, 1.61)            60.8              9
  Europe                         1.43 (1.09, 1.89)            39.3              7
  USA                            1.51 (1.16, 1.95)            65.1              17

Exploring heterogeneity {#s3d}
-----------------------

The influence of a range of a-priori selected study-level and aggregated individual-level parameters on the observed effect estimate was investigated by means of meta-regressions. [Table 7](#pone-0056498-t007){ref-type="table"} summarizes the meta-regression analyses for all 35 results. Heterogeneity could not be explained by any of the 10 considered variables.

10.1371/journal.pone.0056498.t007

###### Meta-regression analysis to explore sources of heterogeneity.

![](pone.0056498.t007){#pone-0056498-t007-7}

                                           Univariate Analyses  
  --------------------------------------- --------------------- -------
  Study Design                                   −.27729         0.137
  Low score study                                .194575         0.389
  Country where the study is conducted                          
  United States                                 Reference       
  Canada                                        −.1738854        0.431
  European countries                            −.0849204        0.726
  Asian Countries                               .1809134         0.686
  Setting                                       −.0286546        0.893
  No of variables adjusted for                  .0251339         0.175
  Method of measuring effect estimate           −.2540725        0.325
  Impact factor of the journal                  −.0067289        0.380
  Method of ascertainment of antibiotic                         
  Patient chart                                 Reference       
  Pharmacy record                               −.0139199        0.955
  Interview                                     .3666586         0.517
  Questionnaire                                 .2703275         0.703
  Combined                                      .0368821         0.905
  Not reported                                  .2469137         0.381
  Proportion of antibiotic use                  −.0023797        0.588

Publication bias {#s3e}
----------------

[Figure 4](#pone-0056498-g004){ref-type="fig"} displays the contour enhanced funnel plot which showed no evidence of publication bias. This was confirmed by the Egger\'s test (P** = **0.905).

![Contour-enhanced funnel plot\
**of the association between the estimated effect size and its standard error in all studies comparing those exposed and unexposed to H2RA displays areas of statistical significance on a funnel plot.** Contours represent conventional "milestone" levels of statistical significance (e.g., \<0.01, \<0.05, \<0.1). This funnel plot is symmetrical as it is not missing studies in the white area excluding the possibility of publication bias (Egger\'s test, p = 0.905).](pone.0056498.g004){#pone-0056498-g004}

Residual confounding {#s3f}
--------------------

The results of the residual confounding analysis are presented in [Figure 5](#pone-0056498-g005){ref-type="fig"}. Panel A refers to a confounder with a prevalence of 0.20; at this prevalence level, a strong confounder causing a two-fold increased risk of CDI would have to be severely imbalanced between H~2~ blockers users and non users (OREC  = 8.87) in order to fully account for the observed adjusted RR of 1.40. For a very common confounder with a prevalence of 0.40, stronger associations with acid-suppression use and/or CDI would be needed to explain the observed association between acid-suppression use and CDI. At this prevalence level, the confounder would have to be both imbalanced (OREC = 5.87) and increase the CDI risk (2.5-fold) to account for the observed OR, after taking publication bias into account.

![Influence of a hypothetical dichotomous confounder present in 20% (panel A) and 40% (panel B) of the study population, unaccounted for in prior adjustments performed in individual studies.\
The graphs depict what combinations of OREC and RR would be necessary for the confounder to fully account for the observed association between H2RA use and CDI acquisition. Abbreviations: OR~EC~, odds ratio of exposure to the confounder in H2RA non-users vs. H2RA users; RR~CD~, relative risk of CDAD in individuals exposed to the confounder vs. non-exposed.](pone.0056498.g005){#pone-0056498-g005}

Number needed to harm {#s3g}
---------------------

The number needed to harm (NNH) was estimated by using the pooled OR from the meta-analysis [@pone.0056498-Cates1]. A recent large prospective hospital cohort [@pone.0056498-Loo2] reported the incidence of CDI at 14 days after hospital admission in patients receiving antibiotics or not: which was 42/1,000 and 5.4/1000, respectively. Based on these reported baseline risks, the number needed to harm (NNH) was 58, 95% CI (37, 115) and 425, 95% CI (267, 848), respectively. For the general population, the NNH at 1 year was 4549, 95% CI (2860, 9097) at 1 year, based on a baseline incidence of CDI of 48/100,000 person-years [@pone.0056498-Khanna1].

Discussion {#s4}
==========

Findings {#s4a}
--------

In this rigorously conducted systematic review and meta-analysis, we observed an association between H~2~RAs use and development of CDI. Using the GRADE framework, the evidence supporting this association is considered of moderate quality. Although evidence from observational studies is considered of weak quality, we have ruled out a strong effect of an unmeasured confounder and, therefore, have upgraded its quality to moderate evidence in favor of this association.

The absolute risk of CDI was highest in hospitalized patients receiving antibiotics with an estimated NNH of 58 at 2 weeks. In contrast, the risk was very low (4549) in the general population. We also observed that, on average, 19% of CDI cases had not been recently exposed to antibiotics.

These findings add to previous subgroup analyses of a limited number of H~2~RA studies performed in a recent systematic review of the association between PPI and CDI. In this review, Kwok [@pone.0056498-Kwok1] et al conducted a subgroup analysis of 15 H~2~RA studies and reported a pooled effect estimate of 1.50, 95% CI (1.23--1.83). Similarly, Leonard et al [@pone.0056498-Leonard1] reported in 2007 an analysis based on 12 studies that showed H~2~RAs use was also associated with risk of CDI with a pooled OR 1.40, 95% CI (0.85--2.29).

Biologic plausibility {#s4b}
---------------------

The pathogenic mechanisms operative in H~2~RAs therapy causing an increased risk of CDI acquisition are unclear, because gastric acid does not kill gastric *C. difficile* spores. One potential explanation for the association between CDI and gastric acid suppression therapies could be that the vegetative form of *C. difficile*, which is killed by acid, plays a role in pathogenesis. Vegetative forms survive on surfaces and could be ingested by patients [@pone.0056498-Jump1]. Survival of acid-sensitive vegetative forms in the stomach could be facilitated by two primary factors: (1) suppression of gastric acid production by acid-suppressive medications; and (2) presence of bile salts in gastric contents of patients on acid-suppressive therapy. Bile salts, which are mainly found in the small intestine, are present in gastric contents, particularly among patients with gastro-esophageal reflux disease (GERD).

The extent of gastric acid suppression could play an important role in potentiating the risk of infection. Kwok [@pone.0056498-Kwok1] et at compared the risk of CDI with gastric acid suppression from 15 studies that reported on estimates of both PPI and H~2~RAs independently on their sample of participants and found that PPI is associated with higher risk of infection in comparison to H~2~RAs though both increase the risk.

Implications {#s4c}
------------

Our findings have global implications both on the inappropriate use of acid-suppression therapy and on the increasing incidence of CDI.

Given the relatively low NNH (58 patients) needed to cause a case of CDI in hospitalized patients receiving antibiotics it becomes necessary to judiciously use H~2~RAs in these patients. In addition, reducing the inappropriate use of acid-suppression medications in this patient population could lead to a significant reduction in the incidence of CDI.

On the other hand, our findings are re-assuring to the public that H~2~RAs use in the general population as over-the-counter medications do not pose significant CDI risk and is associated with a high NNH.

Strengths {#s4d}
---------

Our study has several important strengths. This review is the first systematic evaluation dedicated to examine the association between H~2~RAs and risk of CDI. It includes a comprehensive, up-to-date literature search and formal assessment of the methodological quality of pertinent studies with the largest number of relevant studies as compared to previous reviews [@pone.0056498-Kwok1],[@pone.0056498-Leonard1]. In addition, our pooled estimates are based on multivariate ORs of studies adjusting for several important CDI risk factors. We also performed subgroup analyses and sensitivity analyses that confirmed the robustness of our main results. There was no statistical evidence of publication bias and the effect of residual confounding on the observed association was examined. Finally, the NNH in different risk groups was calculated to aid physicians and patients in making a decision to use H~2~RA or not.

Limitations {#s4e}
-----------

Our review has certain limitations. There was moderate between-study heterogeneity; however, this is often the case in meta-analyses of large observational studies [@pone.0056498-Coory1]--[@pone.0056498-Higgins2]. Moreover the majority of studies pointed towards a positive association. There was virtually no qualitative heterogeneity, and subgroup and sensitivity analyses showed results consistent with the main analysis. There are many patient level parameters which may have led to substantial heterogeneity. Nevertheless, investigating these variables is only possible with individual patient data meta-analysis.

Conclusions {#s5}
===========

In this rigorous systematic review and meta-analysis, we observed an association between H~2~RAs and CDI. The absolute risk of CDI associated with H~2~RAs was highest in hospitalized patients receiving antibiotics. On the other hand, our findings are re-assuring that H~2~RAs use in the general population as over-the-counter medications do not pose a significant CDI risk.
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